GS
Therapeutic Areas
Biodexa Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| eRapa | Familial Adenomatous Polyposis (FAP) | Phase 3 |
| MTX240 (OPB-171775) | TKI-resistant Gastrointestinal Stromal Tumors (GIST) | Pre-clinical/Phase 1 |
| Tolimidone | Type 1 Diabetes | Pre-clinical |